A capsule containing a plant extract and a capsule containing an active pharmaceutical ingredient can look identical, be produced on comparable equipment and sit next to each other on the same shelf. Legally they belong to two different worlds, and companies that move from one category to the other are often surprised by how much changes.
This article sets out the practical differences that affect sourcing, registration and commercialisation.
The distinction is intended use, not composition
A medicinal product is defined by its purpose: preventing or treating disease, or restoring, correcting or modifying a physiological function through a pharmacological, immunological or metabolic action. A food supplement is a foodstuff intended to complement a normal diet, based on nutrients or other substances with a nutritional or physiological effect.
The consequence is decisive. The same substance, at different dosages or with different claims, can fall into either category depending on the market. This is why a product legally sold as a supplement in one country may require a medicinal authorisation in another.
Authorisation versus notification
A medicinal product requires a marketing authorisation: a dossier assessed by the authority before the product reaches the market, covering quality, safety and efficacy.
Nutraceuticals generally follow a notification regime. In the European Union, food supplements fall under the Food Supplements Directive and national implementations, and are normally notified to the competent national authority rather than authorised in advance. Responsibility for compliance sits with the company placing the product on the market.
Faster access, therefore, but not lighter responsibility: the burden shifts from a pre-market assessment to the company’s own documentation and controls.
Claims are where most problems arise
For supplements in the European Union, health claims are governed by a regulation and a register of permitted claims. A claim that is not authorised cannot be used, however plausible it sounds and whatever the literature suggests.
Two practical consequences follow. First, packaging and marketing material cannot simply be translated from one market to another. Second, a claim that crosses into treatment or prevention of disease effectively reclassifies the product as a medicine, with all the consequences that entails.
What changes for sourcing
For anyone buying these products, the differences show up immediately:
- Documentation. A supplement is supported by specifications, certificates of analysis, stability data and safety documentation for the ingredients, not by a registration dossier.
- Manufacturing standards. Food supplement production follows food hygiene and HACCP requirements. Many sites also work to pharmaceutical standards, which is an advantage but not a legal requirement.
- Permitted ingredients and maximum levels. These vary considerably from country to country, and a formulation compliant in one market may need reformulation in another.
- Labelling. Mandatory information, language and claim wording are defined nationally and are often the longest part of a launch.
- Timelines. Market entry is usually faster, which changes forecasting and stock planning.
A category that keeps moving
The boundary is not fixed. Novel food rules, changes to permitted ingredient lists and national interpretations all shift over time, and a product compliant today may require adjustment tomorrow. Working with partners who track the destination market, rather than assuming European rules apply everywhere, is what prevents a launch from stalling at customs.
Both categories, one partner
Synergy Swiss Pharma supplies nutraceutical products alongside its pharmaceutical portfolio, which means the regulatory framework of the destination market is verified before an offer is made rather than afterwards. The full range of categories is listed under products.
For companies looking for a manufacturing partner for supplements or finished dosage forms, contract manufacturing projects are handled through Synergy Swiss Business Development. Further questions are answered in the FAQ section.
Related reading
- Out-licensing a finished dosage form: how it works — from first contact to registration, what each side brings to a licensing agreement
- Why source pharmaceutical products through Switzerland — what a Swiss intermediary adds between a manufacturing site and a destination market
- CEP, DMF or ASMF: which regulatory route for which market — how the three dossier routes differ and which one your destination market actually accepts
Planning a nutraceutical launch in a new market?
